Contributions
Abstract: PB1610
Type: Publication Only
Session title: Lymphoma Biology & Translational Research
Background
Clonal immunoglobulin and T cell receptor gene rearrangements can be used as tumor-specific markers in patients with non-Hodgkin lymphoma.
Aims
The aim of our study was to evaluate the applicative value of standardized BIOMED-2 gene clonality assay protocols for monitoring of lymphoma recurrence.
Methods
With this purpose, 448 specimens from 93 patients with non-Hodgkin lymphoma submitted for initial diagnosis, post-treatment monitoring and evaluation of lymphoma progression or recurrence from 2011-2020 were retrospectively analyzed. According to the initial diagnosis, our series comprised 65 samples from 23 patients with B-cell lymphomas and 383 samples from 70 patients with non-Hodgkin T-cell lymphomas. Clonality testing and determination of amplicon sizes was performed using the BIOMED-2 clonality assays.
Results
We detected clonal immunoglobulin heavy chain gene (IGH) rearrangements with amplicons of same sizes as at initial diagnosis in all follow-up samples from patients with B cell non-Hodgkin lymphoma (100%). In a group of T cell lymphomas we detected clonal T cell receptor beta (TCRB) or gamma (TCRG) gene rearrangements with amplicons of same sizes as at initial diagnosis in 376 follow-up samples from 62 patients (95.6%).
Conclusion
In the present study, we confirmed the utility of standardized BIOMED-2 clonality assays not only for initial diagnosis of wide range of lymphoid proliferations but also for post-treatment monitoring and evaluation of lymphoma progression or recurrence.
Keyword(s): Immunoglobulin gene, Recurrence, TCR
Abstract: PB1610
Type: Publication Only
Session title: Lymphoma Biology & Translational Research
Background
Clonal immunoglobulin and T cell receptor gene rearrangements can be used as tumor-specific markers in patients with non-Hodgkin lymphoma.
Aims
The aim of our study was to evaluate the applicative value of standardized BIOMED-2 gene clonality assay protocols for monitoring of lymphoma recurrence.
Methods
With this purpose, 448 specimens from 93 patients with non-Hodgkin lymphoma submitted for initial diagnosis, post-treatment monitoring and evaluation of lymphoma progression or recurrence from 2011-2020 were retrospectively analyzed. According to the initial diagnosis, our series comprised 65 samples from 23 patients with B-cell lymphomas and 383 samples from 70 patients with non-Hodgkin T-cell lymphomas. Clonality testing and determination of amplicon sizes was performed using the BIOMED-2 clonality assays.
Results
We detected clonal immunoglobulin heavy chain gene (IGH) rearrangements with amplicons of same sizes as at initial diagnosis in all follow-up samples from patients with B cell non-Hodgkin lymphoma (100%). In a group of T cell lymphomas we detected clonal T cell receptor beta (TCRB) or gamma (TCRG) gene rearrangements with amplicons of same sizes as at initial diagnosis in 376 follow-up samples from 62 patients (95.6%).
Conclusion
In the present study, we confirmed the utility of standardized BIOMED-2 clonality assays not only for initial diagnosis of wide range of lymphoid proliferations but also for post-treatment monitoring and evaluation of lymphoma progression or recurrence.
Keyword(s): Immunoglobulin gene, Recurrence, TCR